Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for subject:(Blood clotting factors). Showing records 1 – 3 of 3 total matches.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters

1. Molina, Erika de Simone. Avaliação de indução de resposta imunológica ao fator VIII da coagulação humano recombinante no modelo murino de hemofilia A.

Degree: Mestrado, Biotecnologia, 2013, University of São Paulo

O fator VIII da coagulação é utilizado para o tratamento da hemofilia A e pode ser obtido a partir de concentrados do plasma humano ou na sua forma recombinante (rFVIII). Nosso laboratório tem explorado uma alternativa mais eficiente para a produção do rFVIII em células de mamíferos, utilizando um variante artificial do rFVIII humano (rFVIII-lab). O objetivo principal deste trabalho foi avaliar a imunogenicidade do rFVIII-lab utilizando camundongos modelo da hemofilia A, tendo como objetivos experimentais a purificação, caracterização de atividade funcional in vivo e caracterização de imunogenicidade do rFVIII-lab comparada a produtos de referência, um derivado de plasma e outro recombinante. Os resultados indicam que o perfil de imunogenicidade observado para o rFVIII-lab foi menos intenso e a atividade funcional observada foi similar quando comparado aos produtos de referência. A expectativa é que o presente estudo contribua para o estabelecimento de uma plataforma de produção do rFVIII no país visando o tratamento dos pacientes hemofílicos brasileiros.

Factor VIII (FVIII) replacement therapy employing either FVIII concentrates from blood plasma or recombinant FVIII is the standard of care for management of hemophilia A. Our group has been exploring a more efficient alternative for recombinant FVIII production in mammalian cells employing an engineered artificial variant of the protein (rFVIII-lab). The main objective of this study was to evaluate the immunogenicity of the rFVIII-lab using a murine model of hemophilia A and the specific experimental objectives were to purify, evaluate the in vivo functional activity and the immunogenicity of rFVIII-lab compared to plasma derived and recombinant reference products. Data revealed reduced immunogenicity of rFVIII-lab whereas functional activity was similar when compared to the reference products. The presented study is expected to contribute to the establishment of a locally production platform for the rFVIII aiming at the treatment of Brazilian hemophilic patients.

Advisors/Committee Members: Demasi, Marcos Angelo Almeida.

Subjects/Keywords: Bio pharmacology; Biofarmacologia; Blood clotting factors; Camundongos; Fatores de coagulação sanguínea; Hemofilia; Hemophilia; Immunogenetics; Imunogenética; Mice

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Molina, E. d. S. (2013). Avaliação de indução de resposta imunológica ao fator VIII da coagulação humano recombinante no modelo murino de hemofilia A. (Masters Thesis). University of São Paulo. Retrieved from http://www.teses.usp.br/teses/disponiveis/87/87131/tde-06112013-110452/ ;

Chicago Manual of Style (16th Edition):

Molina, Erika de Simone. “Avaliação de indução de resposta imunológica ao fator VIII da coagulação humano recombinante no modelo murino de hemofilia A.” 2013. Masters Thesis, University of São Paulo. Accessed September 25, 2020. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-06112013-110452/ ;.

MLA Handbook (7th Edition):

Molina, Erika de Simone. “Avaliação de indução de resposta imunológica ao fator VIII da coagulação humano recombinante no modelo murino de hemofilia A.” 2013. Web. 25 Sep 2020.

Vancouver:

Molina EdS. Avaliação de indução de resposta imunológica ao fator VIII da coagulação humano recombinante no modelo murino de hemofilia A. [Internet] [Masters thesis]. University of São Paulo; 2013. [cited 2020 Sep 25]. Available from: http://www.teses.usp.br/teses/disponiveis/87/87131/tde-06112013-110452/ ;.

Council of Science Editors:

Molina EdS. Avaliação de indução de resposta imunológica ao fator VIII da coagulação humano recombinante no modelo murino de hemofilia A. [Masters Thesis]. University of São Paulo; 2013. Available from: http://www.teses.usp.br/teses/disponiveis/87/87131/tde-06112013-110452/ ;

2. Andrade, Cássia Maria Ramaciotti de. Desenvolvimento de processo de produção de fator VIII recombinante em biorreator.

Degree: PhD, Biotecnologia, 2013, University of São Paulo

A utilização de células humanas para a produção do fator VIII de coagulação recombinante (rFVIII) visa obter padrões de glicosilação equivalentes aos encontrados na proteína normal. O objetivo do trabalho foi obter um processo de produção do rFVIII em biorreator em perfusão, devido à sua labilidade térmica. Foram realizados estudos preliminares em Spinner e biorreator utilizando uma linhagem de rHeLa, cujos resultados embasaram os estudos com a linhagem produtora rSkHep. Foram utilizados microcarregadores nos cultivos com esta linhagem devido à dificuldade de adaptação da mesma à suspensão. Ensaios preliminares identificaram a melhor condição de cultivo com 3 g/L Mic e 1 cel/mic e, a partir destes valores, realizou-se um ensaio em perfusão, com tempo de residência de 24 h, no qual as variáveis controladas foram mantidas constantes durante três tempos de residência. A concentração de rFVIII obtida foi semelhante 2 UI/ mL.

The interest in using human cells for the recombinant coagulation factor VIII (rFVIII) lies in obtaining glycosylation patterns similar to the ones found in the normal protein. The objective of this work was to obtain a process for rFVIII production in bioreactor, in perfusion mode, due to the thermal lability of the protein. Using a recombinant HeLa cell line adapted to suspension growth a group of studies in a bioreactor in batch mode were performed. These results were the basis for the studies performed with the producing cell line rSkHep. Microcarriers (micc) were used due to the harshness to adapt the cell line to suspension and to serum-free medium. Preliminary tests identified the best culture condition with 3 g micc/L and 3 cell/micc and, from its values, it was performed a bioreactor study in perfusion mode, with a residence time of 24 hours. The controlled variables were kept constant for three residence times. The maximum rFVIII concentration obtained was 2 UI/mL.

Advisors/Committee Members: Augusto, Elisabeth de Fatima Pires.

Subjects/Keywords: Blood clotting factors; Cellular metabolism; Fatores de coagulação sanguínea; Metabolismo celular; Plasma; Plasma; Proteínas recombinantes; Recombinant proteins

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Andrade, C. M. R. d. (2013). Desenvolvimento de processo de produção de fator VIII recombinante em biorreator. (Doctoral Dissertation). University of São Paulo. Retrieved from http://www.teses.usp.br/teses/disponiveis/87/87131/tde-06112013-105355/ ;

Chicago Manual of Style (16th Edition):

Andrade, Cássia Maria Ramaciotti de. “Desenvolvimento de processo de produção de fator VIII recombinante em biorreator.” 2013. Doctoral Dissertation, University of São Paulo. Accessed September 25, 2020. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-06112013-105355/ ;.

MLA Handbook (7th Edition):

Andrade, Cássia Maria Ramaciotti de. “Desenvolvimento de processo de produção de fator VIII recombinante em biorreator.” 2013. Web. 25 Sep 2020.

Vancouver:

Andrade CMRd. Desenvolvimento de processo de produção de fator VIII recombinante em biorreator. [Internet] [Doctoral dissertation]. University of São Paulo; 2013. [cited 2020 Sep 25]. Available from: http://www.teses.usp.br/teses/disponiveis/87/87131/tde-06112013-105355/ ;.

Council of Science Editors:

Andrade CMRd. Desenvolvimento de processo de produção de fator VIII recombinante em biorreator. [Doctoral Dissertation]. University of São Paulo; 2013. Available from: http://www.teses.usp.br/teses/disponiveis/87/87131/tde-06112013-105355/ ;


Kristianstad University

3. Khashayar, Mahdavisabet. Påverkan på PK(INR)-värdet efter olika preanalytiska behandlingar i venöst humanblod.

Degree: Education and Environment, 2015, Kristianstad University

Venous thromboembolism that cause blood clotting in blood vessels, prevent blood circulation, depending on changes in one or more of the coagulation factors II, VII, IX and X. Patients who have had a blood clot or cardiovascular diseases are treated with oral anti-vitamin K (Warfarin®) to reducing and prevent relapse. Warfarin is also used as a preventive treatment before the disease. An overdose of Warfarin® may cause bleeding-complications and low dose cause blood clotting. The dosage of the drug is controlled by measuring prothrombin in plasma. The aim of this study was to investigate if prothrombin-complex value changes due to re-spinning and re-analysis after six hours. Fitty whole blood samples from warfarin-treated patients were divided into three subgroups, those with protrombinkomplex-values of 2-4 (n=20), >4 (n=15) and <2 (n=15). The samples were centrifugated and measured (Method A), re-centrifugated and measured (Method B) or re-analysed after six hours (Method C). All results were compared in a Bland-Altman plot as follows: Method B vs. Method A and Method C vs. Method A. The scatter graph yielded a strong correlation between Method A and Method B (R2=0.9984) and Method A and Methods C (R2=0.9977). The results from t-test showed a significance level (p<0.001) for both analyses (statistical significance=p<0.05). In this study we showed that prothrombin complex value ware stable after re-centrifugation and re-measurement after six hours. Statistical calculations yielded a strong correlation between the methods (A, B, C), and there was no significance difference between the methods.

Subjects/Keywords: Venous thromboembolism; prothrombin complex; Warfarin®; anti-vitamin K; re-spin; blood clotting; coagulation factors; Venös tromboembolism; protrombinkomplex; antivitamin-K; waran; återcentrifugering; blodproppar; koagulationsfaktorer; Medicinal Chemistry; Läkemedelskemi; Biomedical Laboratory Science/Technology; Biomedicinsk laboratorievetenskap/teknologi

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Khashayar, M. (2015). Påverkan på PK(INR)-värdet efter olika preanalytiska behandlingar i venöst humanblod. (Thesis). Kristianstad University. Retrieved from http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-15316

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Khashayar, Mahdavisabet. “Påverkan på PK(INR)-värdet efter olika preanalytiska behandlingar i venöst humanblod.” 2015. Thesis, Kristianstad University. Accessed September 25, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-15316.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Khashayar, Mahdavisabet. “Påverkan på PK(INR)-värdet efter olika preanalytiska behandlingar i venöst humanblod.” 2015. Web. 25 Sep 2020.

Vancouver:

Khashayar M. Påverkan på PK(INR)-värdet efter olika preanalytiska behandlingar i venöst humanblod. [Internet] [Thesis]. Kristianstad University; 2015. [cited 2020 Sep 25]. Available from: http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-15316.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Khashayar M. Påverkan på PK(INR)-värdet efter olika preanalytiska behandlingar i venöst humanblod. [Thesis]. Kristianstad University; 2015. Available from: http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-15316

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

.